13F filer · CIK 1103804 ↗
Viking Global
You are looking at Q2 2022. See the latest, Q2 2026 →
Reported value
$21.86B
−12% on the quarter before
Positions
82
15 new · 24 sold out
Top 10
35.4%
of the value
Est. gain
−$3.09B
on stocks held all quarter
Est. return
−16.4%
on those stocks since Q1 2022
Positions as of Jun 30, 2022, from Viking Global's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2022. Striped tiles are options.
Largest buys
Since Q1 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Elevance Health Inc~$638.7MAdded · 0.3% → 3.2%+1,323,590 shares
- Mckesson Corp~$530.3MNew · 0.0% → 2.4%+1,625,515 shares
- American Intl Group Inc~$516.9MNew · 0.0% → 2.4%+10,108,715 shares
- Intuit~$430.0MNew · 0.0% → 2.0%+1,115,487 shares
- Block~$316.6MAdded · 0.2% → 1.6%+5,151,673 shares
- Lam Research~$295.8MNew · 0.0% → 1.4%+694,026 shares
- Meta~$267.1MAdded · 1.1% → 2.1%+1,656,262 shares
- Thermo Fisher Scientific Inc~$205.3MAdded · 1.2% → 2.1%+377,891 shares
- Dollar Gen Corp New~$177.2MAdded · 0.3% → 1.2%+721,857 shares
- Take-Two Interactive Softwar~$172.9MAdded · 0.4% → 1.1%+1,411,226 shares
Largest sells
Since Q1 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Comcast Corp New~$659.2MSold out · 2.7% → 0.0%−14,078,668 shares
- T-Mobile Us Inc~$571.5MCut · 7.0% → 5.6%−4,247,782 shares
- Match Group Inc New~$298.4MSold out · 1.2% → 0.0%−2,744,468 shares
- Xp Inc~$284.2MSold out · 1.1% → 0.0%−9,443,312 shares
- Otis Worldwide Corp~$272.3MSold out · 1.1% → 0.0%−3,538,164 shares
- General Electric Co~$258.4MCut · 4.7% → 2.5%−4,058,177 shares
- Aon Plc~$239.6MCut · 2.1% → 0.9%−888,441 shares
- Tenet Healthcare Corp~$192.0MSold out · 0.8% → 0.0%−2,233,647 shares
- Laboratory Corp Amer Hldgs~$191.8MSold out · 0.8% → 0.0%−727,287 shares
- Brookfield Asset Mgmt Inc~$185.6MCut · 3.7% → 2.5%−4,173,794 shares
Holdings
As of Jun 30, 2022. Changes are in shares against Mar 31, 2022, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| T-Mobile Us IncCOM · shares −32% · price +4.8% | 5.6% | $1.23B | +$56.8M | ||||||||
| AmazonCOM · shares +0.9% · price −38.1% | 3.9% | $860.8M | −$525.2M | ||||||||
| MicrosoftCOM · shares −11% · price −16.7% | 3.5% | $761.0M | −$152.5M | ||||||||
| Parker-Hannifin CorpCOM · shares −3.0% · price −13.3% | 3.5% | $755.5M | −$115.8M | ||||||||
| Chubb LimitedCOM · shares +18% · price −8.1% | 3.4% | $741.9M | −$55.4M | ||||||||
| MastercardCL A · shares +28% · price −11.7% | 3.3% | $726.3M | −$75.1M | ||||||||
| Elevance Health IncCOM · shares +939% · price −1.8% | 3.2% | $706.7M | −$1.2M | ||||||||
| Centene Corp DelCOM · shares +6.2% · price +0.5% | 3.2% | $701.7M | +$3.3M | ||||||||
| Fortive CorpCOM · shares −1.9% · price −10.8% | 2.9% | $641.6M | −$77.3M | ||||||||
| International Flavors&FragraCOM · shares +35% · price −9.3% | 2.8% | $610.1M | −$46.4M | ||||||||
| General Electric CoCOM NEW · shares −32% · price −30.4% | 2.5% | $557.1M | −$243.5M | ||||||||
| Boston Scientific CorpCOM · shares +14% · price −15.9% | 2.5% | $546.2M | −$90.1M | ||||||||
| Brookfield Asset Mgmt IncCL A LTD VT SH · shares −26% · price −21.4% | 2.5% | $539.5M | −$146.8M | ||||||||
| Mckesson CorpCOM · shares New | 2.4% | $530.3M | — | ||||||||
| Royalty Pharma PlcSHS CLASS A · shares +15% · price +7.9% | 2.4% | $520.1M | +$33.2M | ||||||||
| American Intl Group IncCOM NEW · shares New | 2.4% | $516.9M | — | ||||||||
| Hdfc Bank LtdSPONSORED ADS · shares +30% · price −10.4% | 2.3% | $504.7M | −$45.1M | ||||||||
| Api Group CorpCOM STK · shares +0.5% · price −28.8% | 2.3% | $503.5M | −$202.8M | ||||||||
| Visa Inc.COM CL A · shares −1.6% · price −11.2% | 2.3% | $503.2M | −$63.6M | ||||||||
| Thermo Fisher Scientific IncCOM · shares +78% · price −8.0% | 2.1% | $468.6M | −$23.0M | ||||||||
| MetaCL A · shares +137% · price −27.5% | 2.1% | $462.1M | −$73.9M | ||||||||
| Marsh & Mclennan Cos IncCOM · shares +26% · price −8.9% | 2.0% | $439.1M | −$34.1M | ||||||||
| IntuitCOM · shares New | 2.0% | $430.0M | — | ||||||||
| Biomarin Pharmaceutical IncCOM · shares +35% · price +7.5% | 1.9% | $418.7M | +$21.7M | ||||||||
| Roivant Sciences LtdSHS · shares 0% · price −17.6% | 1.6% | $359.1M | −$76.8M | ||||||||
| Total · 82 positions | 100% | $21.86B | −$3.09B |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q1 2022 to Q2 2022: 66 stocks held throughout, down $3.09B (−16.4%).
- Ke Hldgs Inc+$58.1M+45%
- T-Mobile Us Inc+$56.8M+5%
- Amylyx Pharmaceuticals Inc+$46.0M+50%
- Royalty Pharma Plc+$33.2M+8%
- Biomarin Pharmaceutical Inc+$21.7M+7%
- Uber−$158.9M−43%
- Adaptive Biotechnologies Cor−$173.7M−42%
- Api Group Corp−$202.8M−29%
- General Electric Co−$243.5M−30%
- Amazon19:1 split−$525.2M−38%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out, 1 split read into the share counts.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $35.08B−2% | SEC ↗ |
| Q1 2026 | May 15, 2026 | $35.75B−5% | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | $37.68B−2% | SEC ↗ |
| Q3 2025 | Nov 14, 2025 | $38.50B+11% | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | $34.59B+10% | SEC ↗ |
| Q1 2025 | May 15, 2025 | $31.48B+2% | SEC ↗ |
| Q4 2024 | Feb 14, 2025 | $30.90B+13% | SEC ↗ |
| Q3 2024 | Nov 14, 2024 | $27.44B+5% | SEC ↗ |
| Q2 2024 | Aug 14, 2024 | $26.02B−3% | SEC ↗ |
| Q1 2024 | May 15, 2024 | $26.86B−2% | SEC ↗ |
| Q4 2023 | Feb 14, 2024 | $27.30B+11% | SEC ↗ |
| Q3 2023 | Nov 14, 2023 | $24.64B+1% | SEC ↗ |
| Q2 2023 | Aug 14, 2023 | $24.43B+15% | SEC ↗ |
| Q1 2023 | May 15, 2023 | $21.31B+7% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $19.98B−8% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $21.66B−1% | SEC ↗ |
| Q2 2022 | Aug 15, 2022 | $21.86B−12% | SEC ↗ |
| Q1 2022 | May 16, 2022 | $24.74B−29% | SEC ↗ |
| Q4 2021 | May 16, 2022 (amended) | $34.71B−5% | SEC ↗ |
| Q3 2021 | May 16, 2022 (amended) | $36.46B+11% | SEC ↗ |
| Q2 2021 | Aug 16, 2021 | $32.98B−2% | SEC ↗ |
| Q1 2021 | May 17, 2021 | $33.58B−8% | SEC ↗ |
| Q4 2020 | Feb 16, 2021 | $36.37B+31% | SEC ↗ |
| Q3 2020 | Nov 16, 2020 | $27.68B+20% | SEC ↗ |
| Q2 2020 | Aug 7, 2020 | $23.14B+20% | SEC ↗ |
| Q1 2020 | May 13, 2020 | $19.21B−10% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $21.35B+11% | SEC ↗ |
| Q3 2019 | Nov 13, 2019 | $19.20B−14% | SEC ↗ |
| Q2 2019 | Aug 14, 2019 | $22.29B+28% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $17.44B−1% | SEC ↗ |
| Q4 2018 | Feb 14, 2019 | $17.57B−3% | SEC ↗ |
| Q3 2018 | Nov 14, 2018 | $18.06B+3% | SEC ↗ |
| Q2 2018 | Aug 14, 2018 | $17.47B+5% | SEC ↗ |
| Q1 2018 | May 15, 2018 | $16.61B+2% | SEC ↗ |
| Q4 2017 | Feb 14, 2018 | $16.26B+5% | SEC ↗ |
| Q3 2017 | Nov 14, 2017 | $15.44B+4% | SEC ↗ |
| Q2 2017 | Aug 14, 2017 | $14.85B−34% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $22.64B+3% | SEC ↗ |
| Q4 2016 | Feb 14, 2017 | $22.01B−5% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 | $23.18B−2% | SEC ↗ |
| Q2 2016 | Aug 15, 2016 | $23.54B+4% | SEC ↗ |
| Q1 2016 | May 16, 2016 | $22.72B | SEC ↗ |